Condition: Extensive-stage Small-cell Lung Cancer · Sponsor: BioNTech SE
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
This description comes directly from the study's public registry record.
BioNTech clinical trials patient information · +49 6131 9084 · patients@biontech.de
Always discuss trial participation with your own doctor first.
| ACRC Arizona Clinical Research Center | Tucson, Arizona, United States | Recruiting |
| Clermont Oncology Center | Clermont, Florida, United States | Terminated |
| Cancer Care Centers of Brevard, Inc | Palm Bay, Florida, United States | Recruiting |
| Northside Hospital Atlanta | Atlanta, Georgia, United States | Recruiting |
| Illinois Cancer Specialists | Niles, Illinois, United States | Recruiting |
| Fort Wayne Medical Oncology and Hematology, Inc | Fort Wayne, Indiana, United States | Recruiting |
| McFarland Clinic | Ames, Iowa, United States | Recruiting |
| Helen G. Nassif Community Cancer Center | Cedar Rapids, Iowa, United States | Recruiting |
| Baptist Health Hardin Cancer Center | Elizabethtown, Kentucky, United States | Recruiting |
| LSU Health Baton Rouge - North Clinic | Baton Rouge, Louisiana, United States | Recruiting |
| Our Lady of the Lake Hospital, Inc. | Baton Rouge, Louisiana, United States | Recruiting |
| Frederick Health Hospital- James M Stockman Cancer Institute | Frederick, Maryland, United States | Recruiting |
+ 209 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06712355